


DEGLI STUDI DI TRIESTE

ANESTESIOLOGIA


Valutazione del paziente critico



1



2



3



4


CHI E' IL PAZIENTE CRITICO?

Patologie che necessitano di un trattamento immediato con percorsi diagnostico terapeutici preospedalieri e intraospedalieri adeguati

- Shock
- Insufficienza respiratoria acuta
- Stroke - ESA - ICH - SAH
- Sindrome coronarica acuta (NSTEMI - STEMI)
- Arresto cardiaco
- Trauma
- Patologie vascolari (shock emorragico)
- Patologie renali gravi



5



6

CRITERI DI GRAVITA'

Frequenza cardiaca < 40 bpm o >140 bpm
 Pressione sistolica <90 mmHg
 Saturazione arteriosa < 90%
 Riempimento capillare >3 s
 Decadimento neurologico - GCS

Instabilità emodinamica

Segni clinici:
 Astenia
 Dispnea (con o senza cianosi)
 Dolore toraco addominale
 Pallore cutaneo, cute fredda, sudorazione profusa e algida
 Tachicardia o bradicardia (aritmie)
 Stato di agitazione, alterazioni dello stato di coscienza (confusione, sopore)
 Turgore delle giugulari, stasi epatica, edemi arti inferiori
 Contrazione della diuresi



7

SHOCK


Riduzione della PA associata a sintomi e segni di ipoperfusione tissutale secondaria a:

IPTENSIONE
IPOPERFUSIONE
ALTERAZIONE CELLULARE

(< flusso sanguigno): Inadeguata perfusione tissutale
 Inadeguato trasporto/disponibilità di O₂

(sepsi): Alterazione utilizzo cellulare di O₂
 Insoddisfatte esigenze metaboliche cellulari


Ipotensione riduce la perfusione e di conseguenza apporto di O₂ e metaboliti
 Alterazioni metaboliche cellulari e nel tempo anche d'organo



8

SHOCK

Definizione:
 Insufficienza acuta del circolo periferico con tendenza all' irreversibilità, ad eziologia molteplice che determina ipoperfusione tissutale ed anossia cellulare.




9

Types of Shock

- Hypovolemic Shock**
 - Cause: Severe blood or fluid loss (e.g., hemorrhage, dehydration).
 - Pathophysiology: Reduced circulating volume leads to inadequate tissue perfusion.
 - Clinical Presentation: Tachycardia, hypotension, cold extremities, and oliguria.
- Cardiogenic Shock**
 - Cause: Heart pump failure (e.g., myocardial infarction, heart failure).
 - Pathophysiology: Impaired cardiac output despite adequate intravascular volume.
 - Clinical Presentation: Hypotension, distended jugular veins, pulmonary edema.
- Distributive Shock**
 - Cause: Abnormal blood distribution (e.g., septic shock, anaphylactic shock, neurogenic shock).
 - Pathophysiology: Vasodilation causes a relative hypovolemia despite normal or increased cardiac output.
 - Clinical Presentation: Warm extremities (septic), hypotension, altered mental status.
- Obstructive Shock**
 - Cause: Mechanical obstruction of the heart or great vessels (e.g., pulmonary embolism, cardiac tamponade).
 - Pathophysiology: Impaired ventricular filling or emptying, leading to decreased cardiac output.
 - Clinical Presentation: Hypotension, jugular vein distention, pulsus paradoxus.

10



11

Tipi di SHOCK

- Puri
- Misti

- persistere evento patogenetico
- validita' risposta sistemica
- tempestivita' ed adeguatezza intervento terapeutico

Caratteristiche

ipovolemia assoluta (emorragia)
 vasoplegia (trauma midollo spinale)
 alterazione cardiaca (trauma toracico)
 iperdinamismo circolatorio (sepsi post-traumatica)

ERP 2022

12

Tipi di SHOCK

Settico (62%) ... ICU
 Cardiogeno (16%)
 Ipovolemico (16%)
 Emorragico: Aree urbane, trauma center
 Distributivo (4%)
 Ostruttivo (2%)

Tipi di shock

1. Diminuzione del volume di liquidi
 - 1.1 shock ipovolemico
2. Aumento del diametro dei vasi
 - 2.1 shock neurogeno
 - 2.2 shock anafilattico
 - 2.3 shock settico
3. Diminuzione della capacità contrattile del cuore
 - 3.1 shock cardiogeno

Perdita volume
 Vasodilatazione periferica
 Fallimento di pompa

ERP 2022

13

SHOCK CARDIOGENO

Cardiogenic Shock
 Progressive Cycles of Inflammation, Ischemia, Vasoconstriction, and Volume Overload

Primary Cardiac Insult Myocardial Dysfunction

Manifestations of Cardiogenic Shock

- Systolic Blood Pressure < 90 mm Hg (or reduction > 40 mmHg)
- Cardiac Index < 2.2 L/min/m²
- Cardiac Power Output < 0.6 W
- Lactic acidosis

Causes of Primary Cardiac Insult:

- Myocardial Infarction
- Myocardial Dysfunction
- Myocarditis
- Severe Aortic Stenosis
- Severe Mitral Regurgitation
- Systemic Hypertension
- Coronary Artery Disease
- Aortic Dissection

Pathophysiology:

- Sympathetic Stimulation
- Renin-Angiotensin Activation
- Neurohormonal Feedback
- Vasoconstriction

Progression:

- Organ Perfusion
- Volume Overload
- Myocardial Dysfunction
- Blood Pressure
- Vasoconstriction
- Death

ERP 2022

14

Cardiogenic Shock Overview

Mechanisms of Origin

Cause: Primary pump failure of the heart due to:

- Acute myocardial infarction (most common)
- Severe heart failure
- Cardiac tamponade
- Valvular dysfunction (e.g., mitral regurgitation, aortic stenosis)

Pathophysiology:

- Increased stroke volume → low cardiac output
- Inadequate perfusion of vital organs → tissue hypoxia

Progression

Initial Stage: Ischemia reduces cardiac contractility.

Compensatory Stage: Sympathetic activation increases heart rate and systemic vascular resistance.

Decompensation: Failure of compensatory mechanisms leads to:

- Severe tissue hypoxia
- Metabolic acidosis
- Multiorgan dysfunction syndrome (MODS)

Cardiogenic Shock

Acute MI → Decreased coronary perfusion → Ischemia → Reduced and/or occlusion of coronary artery → Myocardial injury/death → Hypotension → Decreased CO → Vicious Cycle of Cardiac Injury → Acute Decompensated HF, Cardiomyopathy, Myocarditis

15

Cardiogenic Shock Manifestations & Treatment

Clinical Manifestations

- Cardinal: Hypotension, tachycardia, elevated JVP, cold extremities
- Pulmonary: Pulmonary edema, dyspnea, hypoxemia
- Renal: oliguria
- Cerebral: Altered mental status (confusion, lethargy)

Treatment Strategies

Initial Stabilization

- Oxygenation: supplemental oxygen or mechanical ventilation
- Fluid resuscitation: support
- Inotropes (e.g., Dobutamine) for contractility, Loop diuretics (e.g., furosemide) to maintain JVP.

Revascularization

- PCI or CABG of myocardial infarction.

Mechanical Support

- IABP, VADs, or ECMO in refractory cases.

Treat Underlying Cause: Valve repair, replacement, arrhythmia treatment.

Cardiogenic shock management

A. Etiologic therapy
Coronary artery revascularization, ventricular disease management, arrhythmic and conduction disorders management

B. Optimizing Hemodynamics

1- Improve Tissue Perfusion

If increase venous pressure and/or pulmonary congestion → Diuretics (see: Heart failure management therapy)

If low blood pressure → Treated other causes of vasoplegic shock(s.)
Management: Vasopressors

2- Improve Pump Function

If Decrease RV or LV contractility → Inotropes: Dobutamine (Dilatoric, Levosimendan)

Manage Heart rate: Reduction of tachy- or bradycardia improves RV or LV conduction disorder, improving

If RV filling inadequate → Inotropes (e.g., Dobutamine) for contractility, Loop diuretics (e.g., furosemide) to maintain JVP.
Volume expansion, Decrease entry wall pressure, Decrease intrathoracic pressure

If LV filling inadequate → Volume expansion, Decrease intrathoracic pressure, Reduce obstruction

C. Manage other organ dysfunction

Organism
Non- or limited Mechanical Ventilation
Reduce metabolic waste, maintain, separate
Acidosis and/or metabolic control. Renal replacement therapy

If refractory cardiogenic shock, consider acute mechanical circulatory support

16

Obstructive Shock Overview

Types of Obstructive Shock

Pulmonary Embolism (PE): Large clots obstruct pulmonary circulation.

Cardiac Tamponade: Fluid accumulates in the pericardium, compressing the heart.

Tension Pneumothorax: Air trapped in the pleural space increases intrathoracic pressure, compressing the heart and lungs.

Aortic Dissection: A tear in the aortic wall disrupts blood flow.

Mechanisms of Origin

Pulmonary Embolism: Obstruction of the pulmonary arteries increases right ventricular afterload, leading to reduced cardiac output.

Cardiac Tamponade: Excess fluid restricts heart expansion, reducing ventricular filling and output.

Tension Pneumothorax: Increased intrapleural pressure compresses the heart, reducing venous return and cardiac output.

Aortic Dissection: Disruption of blood flow from the aorta leads to impaired perfusion of vital organs.

ERP 2022

17

Obstructive Shock Progression, Manifestations

Progression

- Initial obstruction (e.g., embolism, tamponade) leads to increased pressure and decreased venous return.
- Compensatory Stage**: Sympathetic activation to maintain cardiac output.
- Decompensatory Stage**: Failure to maintain adequate perfusion leads to tissue hypoxia and organ dysfunction.

Clinical Manifestations

- Pulmonary Embolism**: Sudden dyspnea, pleuritic chest pain, tachypnea, hypotension.
- Cardiac Tamponade**: Beck's triad: Hypotension, muffled heart sounds, distended jugular veins.
- Tension Pneumothorax**: Tracheal deviation, hypotension, decreased breath sounds on the affected side.
- Aortic Dissection**: Severe tearing chest pain, unequal blood pressures between arms.

ERP 2022

18

Obstructive Shock Treatment


Treatment Strategies

Pulmonary Embolism:
Anticoagulation (e.g., heparin) or thrombolysis for severe cases.
Surgical/Endovascular embolectomy if unstable.

Cardiac Tamponade:
Immediate pericardiocentesis to remove excess fluid.

Tension Pneumothorax:
Needle decompression followed by chest tube insertion.

Aortic Dissection:
Blood pressure control (e.g., beta-blockers) and surgical repair.




ERP 2022

19

SHOCK DISTRIBUTIVO

Vasodilatazione periferica (mediatori umorali)

Sepsi:
Batteriche (gram+, gram-),
Virali (cytomegalovirus, varicella,
ebola)
Fungine (candida, aspergillo),
Mycobatteri (tbc)



ERP 2022


20

SHOCK DISTRIBUTIVO

Vasodilatazione periferica e discrepanza tra letto circolatorio e volume circolante

Anafilassi (reazione IgE mediata)
Punture insetti, alimenti e farmaci

- Triade: IL2, IL6, TNF alpha
- Mast cell (masticati) rilascia: istamina, prostaglandine e trombossani: vasodilatazione



ERP 2022

21

SHOCK DISTRIBUTIVO

Neurogeno
Traumi midollari, (farmaci antipertensivi)
Danno SN autonomo: < resistenze vascolari e alterato tono vagale

ERP 2022
